The synaptic marker neurogranin as a disease state biomarker in Alzheimer’s disease: a systematic review and meta-analysis

References

• Scheltens P, Blennow K, Breteler MMB, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–517.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016;12(4):459–509.
   PubMedGoogle Scholar
• Zetterberg H, Blennow K. Neurogranin levels in cerebrospinal Fluid: a new addition to the Alzheimer Disease Diagnostic Toolbox. JAMA Neurol. 2015;72(11):1237–1238.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Albert M, Fox N, et al. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016;12(1):60–64.
   PubMed Web of Science ®Google Scholar
• Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535–562.
   PubMed Web of Science ®Google Scholar
• Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572–580.
   PubMed Web of Science ®Google Scholar
• Blennow K, Bogdanovic N, Alafuzoff I, et al. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transmission. 1996;103(5):603–618.
   PubMed Web of Science ®Google Scholar
• Minger SL, Honer WG, Esiri MM, McDonald B, et al. Synaptic pathology in prefrontal cortex is present only with severe dementia in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60(10):929–936.
   PubMed Web of Science ®Google Scholar
• Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 2009;118(1):167–179.
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Riederer P, O’Bryant SE, et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the consensus of the task force on biological markers in psychiatry of the world federation of societies of biological psychiatry. World J Biol Psychiatry. 2018;19(4):244–328.
   PubMed Web of Science ®Google Scholar
• Thorsell A, Bjerke M, Gobom J, et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res. 2010;1362:13–22.
   PubMed Web of Science ®Google Scholar
• Portelius E, Zetterberg H, Skillbäck T, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease. Brain. 2015;138(11):3373–3385.
   PubMed Web of Science ®Google Scholar
• Bos I, Vos S, Verhey F, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimers Dement. 2019;15(5):644–654.
   PubMed Web of Science ®Google Scholar
• De Vos A, Jacobs D, Struyfs H, et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. Alzheimers Dement. 2015;11(12):1461–1469.
   PubMed Web of Science ®Google Scholar
• De Vos A, Struyfs H, Jacobs D, et al. The Cerebrospinal fluid neurogranin/BACE1 ratio is a potential correlate of cognitive decline in Alzheimer's disease. J Alzheimers Dis. 2016;53(4):1523–1538.
   PubMed Web of Science ®Google Scholar
• Sanfilippo C, Forlenza O, Zetterberg H, et al. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD. J Neural Transm. 2016;123(12):1443–1447.
   PubMed Web of Science ®Google Scholar
• Hampel H, Toschi N, Baldacci F, et al. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimers Dement. 2018;14(4):492–501.
   PubMed Web of Science ®Google Scholar
• Kester MI, Teunissen CE, Crimmins DL, et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol. 2015;72(11):1275–1280.
   PubMed Web of Science ®Google Scholar
• Hellwig K, Kvartsberg H, Portelius E, et al. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease. Alzheimers Res Therm. 2015;7:74.
   PubMed Web of Science ®Google Scholar
• Kvartsberg H, Portelius E, Andreasson U, et al. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. Alzheimers Res Ther. 2015;7(1):40.
   Google Scholar
• Mattsson N, Insel PS, Palmqvist S, et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Mol Med. 2016;8(10):1184–1196.
   PubMed Web of Science ®Google Scholar
• Tarawneh R, D’Angelo G, Crimmins D, et al. Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol. 2016;73(5):561.
   PubMed Web of Science ®Google Scholar
• Wellington H, Paterson RW, Portelius E, et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 2016;86(9):829–835.
   PubMed Web of Science ®Google Scholar
• Casaletto KB, Elahi FM, Bettcher BM, et al. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers. Neurology. 2017;89(17):1782–1788.
   PubMed Web of Science ®Google Scholar
• Pereira JB, Westman E, Hansson O. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. Neurobiol Aging. 2017;58:14–29.
   PubMed Web of Science ®Google Scholar
• Schipke CG, De Vos A, Fuentes M, et al. Neurogranin and BACE1 in CSF as potential biomarkers differentiating depression with cognitive deficits from early Alzheimer's disease: a pilot study. Dement Geriatr Cogn Disord Extra. 2018;8(2):277–289.
   PubMed Web of Science ®Google Scholar
• Wellington H, Paterson RW, Suárez-González A, et al. CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. Ann Clin Transl Neurol. 2018;5(2):162–171.
   PubMed Web of Science ®Google Scholar
• Willemse EAJ, De Vos A, Herries EM, et al. Neurogranin as cerebrospinal fluid biomarker for Alzheimer disease: an assay comparison study. Clin Chem. 2018;64(6):927–937.
   PubMed Web of Science ®Google Scholar
• Wang L. Association Association of cerebrospinal fluid Neurogranin with Alzheimer's disease. Aging Clin Exp Res. 2019;31(2):185–191.
   PubMed Web of Science ®Google Scholar
• Antonell A, Tort-Merino A, Rios J, et al. Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimers Dement. 2020;16(2):262–272.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang X, Zhu B, et al. Association of clusterin levels in cerebrospinal fluid with synaptic degeneration across the Alzheimer's disease continuum. Neuropsychiatr Dis Treat. 2020;16:183–190.
   PubMed Web of Science ®Google Scholar
• Reddy PH, Mani G, Park BS, et al. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alzheimers Dis. 2005;7(2):103–117.
   PubMed Web of Science ®Google Scholar
• Davidsson P, Blennow K. Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr. 1998;10(1):11–23.
   PubMedGoogle Scholar
• Guadano-Ferraz A, Vinuela A, Oeding G, et al. RC3/neurogranin is expressed in pyramidal neurons of motor and somatosensory cortex in normal and denervated monkeys. J Comp Neurol. 2005;493(4):554–570.
   PubMed Web of Science ®Google Scholar
• Houben MP, Lankhorst AJ, van Dalen JJ, et al. Pre- and postsynaptic localization of RC3/neurogranin in the adult rat spinal cord: an immunohistochemical study. J Neurosci Res. 2000;59(6):750–759.
   PubMed Web of Science ®Google Scholar
• Watson JB, Sutcliffe JG, Fisher RS. Localization of the protein kinase C phosphorylation/calmodulin-binding substrate RC3 in dendritic spines of neostriatal neurons. Proc Natl Acad Sci USA. 1992;89(18):8581–8585.
   PubMed Web of Science ®Google Scholar
• Sze CI, Bi H, Kleinschmidt-DeMasters BK, et al. Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer’s disease brains. J Neurol Sci. 2000;175(2):81–90.
   PubMed Web of Science ®Google Scholar
• Dominguez-Alvaro M, Montero-Crespo M, Blazquez-Llorca L, et al. Three-dimensional analysis of synapses in the transentorhinal cortex of Alzheimer's disease patients. Acta Neuropathol Commun. 2018;6(1):20.
   PubMedGoogle Scholar
• Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2(10):605–613.
   PubMed Web of Science ®Google Scholar
• Gordon BA, Friedrichsen K, Brier M, et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain. 2016;139(8):2249–2260.
   PubMedGoogle Scholar
• Scheff SW, Price DA, Schmitt FA, et al. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68(18):1501–1508.
   PubMed Web of Science ®Google Scholar
• Green MS, Kaye JA, Ball MJ. The Oregon brain aging study: neuropathology accompanying healthy aging in the oldest old. Neurology. 2000;54(1):105–113.
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–259.
   PubMed Web of Science ®Google Scholar
• Palmqvist S, Insel PS, Stomrud E, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Mol Med. 2019;11(12):e11170.
   PubMed Web of Science ®Google Scholar
• Buchhave P, Minthon L, Zetterberg H, et al. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69(1):98–106.
   PubMed Web of Science ®Google Scholar